背景:最近的研究提出40Hz神经活动诱导是治疗阿尔茨海默痴呆(AD)的一种有希望的方法。然而,传统的闪烁光在解决AD的认知和神经精神症状(NPS)方面是次优的。本研究旨在探讨一种新型多灯具照明技术的临床疗效,减少了可察觉的闪烁,用于治疗ADNPS。
方法:本研究是前瞻性的,方便采样,非随机病例对照调查涉及来自7个日托中心的78例临床诊断的AD患者.35人通过DeltaM+BrainCareLight(M+)暴露于40Hz的光,每天4小时,5天/周,12周。其他43名患者作为对照。临床痴呆评分(CDR-SB)量表的方框总和,神经精神量表(NPI),和Zarit负担访谈(ZBI)在基线和第13周进行评估。
结果:在基线时,这些病例的认知功能较差,较低的认知得分(迷你精神状态检查,p=0.04;认知能力筛查仪,p=0.04),和高级照顾者负担,ZBI评分高于对照组(p<0.01)。干预之后,根据NPI评估,这些病例的NPS有显著改善(p=0.02),尤其是抑郁和欣快感症状(分别为p=0.04和<0.01)和较少的照顾者负担(ZBI评分,p<0.01)。在全局函数中,对照组CDR-SB评分明显下降(p<0.01),而案件没有。
结论:结果表明M+可以减缓整体功能下降,保持认知功能,提高NPS,减轻AD患者的护理负担。需要更大规模的生物标志物研究来探索潜在的机制。
BACKGROUND: Recent studies propose 40 Hz neural activity induction as a promising approach for managing Alzheimer\'s dementia (AD). However, traditional flickering light is suboptimal in addressing cognitive and neuropsychiatric symptoms (NPS) of AD. This study aims to investigate the clinical efficacy of a novel multi-luminaire lighting technology, with reduced perceptible flickering, for treating AD NPS.
METHODS: This study is a prospective, convenient sampling, non-randomized case-control investigation involving seventy-eight clinically diagnosed AD patients from 7 daycare centers. Thirty-five were exposed to 40 Hz light through Delta M + BrainCare Light (M +), 4 h daily, 5 days/week, for 12 weeks. The other 43 patients served as controls. Sum of boxes of the Clinical Dementia Rating (CDR-SB) scale, Neuropsychiatric Inventory (NPI), and Zarit Burden Interview (ZBI) were assessed at baseline and the 13th week.
RESULTS: At baseline, the cases had worse cognitive function, lower cognitive score (Mini-Mental State Examination, p = 0.04; Cognitive Abilities Screening Instrument, p = 0.04), and advanced caregiver burden with higher ZBI scores (p < 0.01) than the controls. After the intervention, the cases had significant improvements in NPS as assessed using the NPI (p = 0.02), especially depression and euphoria symptoms (p = 0.04 and < 0.01, respectively) and less caregiver burden (ZBI score, p < 0.01). In global function, the control group showed a significant decline in CDR-SB score (p < 0.01), while the cases did not.
CONCLUSIONS: Results suggest M + may slow global function decline, preserve cognitive function, improve NPS, and reduce caregiver burden in AD patients. Larger studies with biomarkers are needed to explore underlying mechanisms.